The Evolving Treatment and Clinical Trials of Hepatocellular Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 10413
Special Issue Editors
Interests: hepatocellular carcinoma; gastrointestinal malignancies; cancer metastasis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Over the last few years, the treatment of hepatocellular carcinoma has evolved with the introduction of new systemic therapies as well as recent updates to the Barcelona Clinic Liver Cancer staging system.
We are pleased to invite you to contribute to this Special Issue of Cancers titled: “The Evolving Treatment and Clinical Trials of Hepatocellular Carcinoma”.
This Special Issue aims to review the changing treatment program for hepatocellular carcinoma as well as future directions in the management of patients with HCC.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: advances in medical therapy, including immune-based therapies in the treatment of HCC, mechanisms of resistance to systemic therapies, and advances in surgical and locoregional therapies in the treatment of HCC.
We look forward to receiving your contributions.
Dr. Zachary J. Brown
Dr. John D. Allendorf
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- liver resection
- liver transplant
- transarterial chemoembolization
- immune therapies
- liver disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.